I

    Invivyd Inc. (IVVD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.01 (-1.00%)

    Market Cap: $284.30M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(10/22)
    Avg Surprise
    -84.47%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.13+13.3%
    60d ago$-0.13+13.3%
    30d ago$-0.13+13.3%
    7d ago$-0.13+13.3%
    Current$-0.15
    Revenue Consensus
    $15M
    Range$15M - $16M
    3 analysts
    Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.20 - $-0.20
    1 analysts
    Revenue Consensus
    $13M
    Range$10M - $18M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-0.15---
    Jun 26
    		$-0.14$-0.15+6.67%Beat-16.7%
    Mar 26
    		$-0.13$-0.08-62.50%Miss+7.1%
    Dec 25
    		$-0.04N/A+54.51%Beat+73.8%
    Sep 25
    		$-0.06$-0.09+33.33%Beat+88.2%
    Jun 25
    		$-0.12$0.01-1300.00%Miss+70.0%
    Mar 25
    		$-0.14$-0.04-250.00%Miss+63.2%
    Dec 24
    		$-0.15$-0.10-50.00%Miss+77.6%
    Sep 24
    		$-0.51$-0.35-45.71%Miss-41.7%
    Jun 24
    		$-0.40$-0.39-2.56%Miss+13.0%
    Mar 24
    		$-0.38$-0.39+2.56%Beat-18.8%
    Dec 23
    		$-0.67$-0.42-59.52%Miss-168.0%
    Sep 23
    		$-0.36$-0.50+28.00%Beat+14.3%
    Jun 23
    		$-0.46$-0.45-2.22%Miss+2.1%
    Mar 23
    		$-0.32$-0.48+33.33%Beat+64.8%
    Dec 22
    		$-0.25$-0.39+35.90%Beat+67.5%
    Sep 22
    		$-0.42$-0.37-13.51%Miss+52.8%
    Jun 22
    		$-0.47$-0.50+6.00%Beat-161.1%
    Mar 22
    		$-0.91$-0.56-62.50%Miss+57.5%
    Dec 21
    		$-0.77$-1.03+25.24%Beat-
    Sep 21
    		$-0.89$-0.57-56.14%Miss-
    Jun 21
    		$-0.18N/A+77.50%Beat-
    Mar 21
    		$-2.14$-0.60-256.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio-2.59EV/EBITDA0.78x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-183.90%Operating Margin-320.80%
    ROE-95.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.87xQuick Ratio5.87x
    Trading Statistics
    Beta0.71Avg Volume3.69M
    52-Week High$3.0752-Week Low$0.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.94
    SMA 20$0.81
    SMA 50$0.78
    SMA 200$1.52
    EMA 10$0.91
    EMA 20$0.85
    EMA 50$0.85
    EMA 200$1.20

    MACD

    Line: 0.06Signal: 0.04Hist: 0.02

    ADX

    ADX: 28.1+DI: 30.7-DI: 15.6

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down16.0
    PSAR$1.04

    Bollinger Bands

    Upper Band$1.09
    Lower Band$0.53
    %B Position6893%(Upper)
    Band Width0.76

    RSI (14-Day)

    Neutral
    62.6

    Momentum Oscillators

    Stoch %K71.8
    Stoch %D68.4
    Williams %R-24.4
    ROC (10d)29.0%
    Momentum0.21
    CCI (20d)86.3
    MFI (14d)72.6

    Volatility Measures

    ATR (14d)$0.08(8.3%)
    StdDev (20d)0.14
    Hist Vol105.0%(High)

    Volume Flow

    VWAP$0.97
    OBV384.5M
    AD Line-97.7M
    CMF (20d)0.166

    Volume Metrics

    Avg Vol (20d)3.8M
    Vol Ratio0.8x
    VWMA (20d)$0.84

    Pivot Points

    R3$1.07
    R2$1.02
    R1$0.99
    Pivot Point$0.94
    S1$0.92
    S2$0.87
    S3$0.84

    Advanced Oscillators

    TSI21.52
    Ultimate Osc59.0
    KST351.93

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$14.29M$13.74M$17.21M$13.13M$11.79M$11.30M$13.82M$9.30M$2.26M$0$3.02M$0
    Cost of Revenue$1.27M$1.03M$1.14M$1.09M$685,000$834,000$724,000$806,000$88,000$0$516,000$0
    Gross Profit$13.01M$12.71M$16.07M$12.04M$11.10M$10.47M$13.10M$8.49M$2.18M$0$2.51M$0
    Operating Expenses$58.83M$55.85M$28.62M$23.06M$26.16M$27.39M$32.33M$70.81M$51.42M$46.09M$76.75M$43.06M
    R&D$29.37M$30.73M$10.05M$8.05M$9.57M$10.64M$17.91M$57.85M$30.33M$31.16M$61.66M$30.17M
    SG&A$29.46M$25.12M$18.57M$15.02M$16.59M$16.75M$14.41M$12.96M$21.09M$14.93M$15.09M$12.89M
    Operating Income$-45,820,000$-43,136,000$-12,555,000$-11,023,000$-15,060,000$-16,922,000$-19,229,000$-62,311,000$-49,247,000$-46,089,000$-76,752,000$-43,060,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-44,393,000$-41,400,000$-11,070,000$-10,470,000$-14,660,000$-16,289,000$-18,443,000$-60,739,000$-47,247,000$-43,496,000$-73,654,000$-39,440,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-44,393,000$-41,400,000$-11,070,000$-10,470,000$-14,660,000$-16,289,000$-18,443,000$-60,739,000$-47,247,000$-43,496,000$-73,654,000$-39,440,000
    EBITDA$-43,754,000$-40,887,000$-10,635,000$-10,039,000$-14,157,000$-15,551,000$-16,927,000$-60,180,000$-46,733,000$-42,972,000$-68,004,000$-40,624,000
    EBIT$-44,393,000$-41,400,000$-11,070,000$-10,470,000$-14,660,000$-16,289,000$-18,443,000$-60,739,000$-47,247,000$-43,496,000$-73,654,000$-39,440,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IVVD

    News

    FY2026 EPS Estimates for Invivyd Increased by HC Wainwright

    HC Wainwright has raised its FY2026 EPS estimate for Invivyd to a loss of $0.46 per share from $0.48, maintaining a "Buy" rating. The firm anticipates Invivyd will achieve profitability by FY2028, with EPS reaching $1.10 by FY2030, despite the company recently missing Q2 earnings and revenue expectations with a loss of $0.14 per share. Invivyd continues to report substantial losses and negative margins, and its stock recently traded at $0.96, while analysts maintain a "Hold" consensus rating and an $8.00 average price target.

    MarketBeat•8/20/26•
    Neutral

    Invivyd (IVVD) CCO’s 40,780-share stock sale runs under 10b5-1 plan

    Invivyd, Inc. (IVVD) Chief Commercial Officer Timothy Edward Lee sold 40,780 common shares in August 2026 to cover tax withholding obligations after converting 102,000 restricted stock units. These trades were executed as non-discretionary "sell-to-cover" transactions under a pre-established Rule 10b5-1 trading plan. The sales occurred across two days at weighted average prices of $0.722 and $0.8429.

    Stock Titan•8/19/26•
    Neutral

    Invivyd CHRO Julie Green sells $31,670 in company stock

    Invivyd's Chief Human Resources Officer, Julie Green, sold 40,780 shares of company stock for a total of approximately $31,670 in mid-August 2026. These transactions were "sell-to-cover" sales to meet tax obligations from vested restricted stock units (RSUs), and Green directly holds 168,937 shares afterward. The company also announced the completion of enrollment for its Phase 3 DECLARATION trial for its COVID-19 antibody VYD2311, with top-line data expected soon, and maintains a Buy rating from H.C. Wainwright despite the upcoming termination of PEMGARDA's emergency authorization.

    Investing.com•8/19/26•
    Neutral

    Invivyd (IVVD) CSO sells shares to cover taxes on vested RSUs

    Invivyd, Inc.'s Chief Scientific Officer, Robert D. Allen III, converted 102,000 Restricted Stock Units (RSUs) into common stock on August 15, 2026. Following this, he sold a total of 37,722 shares over two days, August 17 and 18, 2026, at weighted average prices of $0.722 and $0.8429, respectively. These sales were non-discretionary "sell-to-cover" transactions under a Rule 10b5-1 plan to satisfy tax withholding obligations related to the RSU vesting.

    Stock Titan•8/19/26•
    Neutral

    Invivyd CSO Robert Allen III sells $29,295 in stock

    Invivyd CSO Robert Allen III sold $29,295 worth of company stock between August 15-18, 2026, primarily through "sell-to-cover" transactions for tax obligations related to vesting restricted stock units. Concurrently, he acquired 102,000 shares from RSU vesting. The company's stock has seen recent gains but remains down over six months, while Invivyd continues its Phase 3 trials for VYD2311 and faces a future termination of PEMGARDA's EUA.

    Investing.com•8/19/26•
    Neutral

    Frequently Asked Questions About IVVD

    Does IVVD pay dividends?
    Invivyd Inc. (IVVD) does not currently pay a regular dividend.
    What is IVVD's market cap?
    Invivyd Inc. (IVVD) has a market capitalization of $284.30M with a current stock price of $0.95.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In